Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Mar 21, 2026, 19:55Rebecca Mallick: Fertility Must Become Standard in Endometriosis Care
-
Mar 21, 2026, 19:48Kendra Batchelder: The Momentum Behind Women’s Health Innovation
-
Mar 21, 2026, 19:44COVID-19 Vaccination During Pregnancy in 2026 – Weence Health Content Services
-
Mar 21, 2026, 19:37Endometriosis and the Endocannabinoid System – ANTG
-
Mar 21, 2026, 19:35Corina Carpenter: A Guide to Clinical Trial Compensation in San Antonio
-
Mar 21, 2026, 19:31The Signals Behind PCOS – PCOS Awareness Association
-
Mar 21, 2026, 19:26Paternal Impact on Embryo Morphokinetics and ART Success – RBMO
-
Mar 21, 2026, 19:19Christopher Robinson: Maternal Fetal Pharmacokinetics of Azithromycin in Preterm Premature Rupture of Membranes
-
Mar 21, 2026, 19:13Lori Brumat: Why Women’s Health Should Matter to Everyone Right Now